Grace Therapeutics, Inc. (GRCE) - Net Assets

Latest as of September 2025: $62.82 Million USD

Based on the latest financial reports, Grace Therapeutics, Inc. (GRCE) has net assets worth $62.82 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($66.58 Million) and total liabilities ($3.76 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Grace Therapeutics, Inc. liquidity resilience to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric	Value
Current Net Assets	$62.82 Million
% of Total Assets	94.36%
Annual Growth Rate	20.59%
5-Year Change	19.67%
10-Year Change	150.81%
Growth Volatility	107.35

Grace Therapeutics, Inc. - Net Assets Trend (2010–2025)

This chart illustrates how Grace Therapeutics, Inc.'s net assets have evolved over time, based on quarterly financial data. Also explore Grace Therapeutics, Inc. asset portfolio for the complete picture of this company's asset base.

Annual Net Assets for Grace Therapeutics, Inc. (2010–2025)

The table below shows the annual net assets of Grace Therapeutics, Inc. from 2010 to 2025. For live valuation and market cap data, see Grace Therapeutics, Inc. (GRCE) total market value.

Year	Net Assets	Change
2025-03-31	$66.61 Million	+7.88%
2024-03-31	$61.74 Million	-9.14%
2023-03-31	$67.95 Million	-37.24%
2022-03-31	$108.27 Million	+94.52%
2021-03-31	$55.66 Million	+328.35%
2020-03-31	$12.99 Million	+17.65%
2019-03-31	$11.04 Million	+73.44%
2018-03-31	$6.37 Million	-68.30%
2016-03-31	$20.09 Million	-24.37%
2015-03-31	$26.56 Million	-11.21%
2014-03-31	$29.91 Million	+214.90%
2013-03-31	$9.50 Million	-34.74%
2012-03-31	$14.55 Million	+149.49%
2011-03-31	$5.83 Million	+45.19%
2010-03-31	$4.02 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Grace Therapeutics, Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have decreased by 21711341500.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (March 2025)

Component	Amount	Percentage
Common Stock	$1.00K	0.00%
Other Comprehensive Income	$-6.04 Million	-9.06%
Other Components	$293.33 Million	440.38%
Total Equity	$66.61 Million	100.00%

Grace Therapeutics, Inc. Competitors by Market Cap

The table below lists competitors of Grace Therapeutics, Inc. ranked by their market capitalization.

Company	Market Cap
Ashima Limited NSE:ASHIMASYN	$33.08 Million
Zanaga Iron Ore Company Limited F:6ZA	$33.09 Million
Wijaya Karya Bangunan Gedung Tbk PT JK:WEGE	$33.09 Million
Dongil Metal Co. Ltd KQ:109860	$33.10 Million
XPLUS SA ZY -01 F:75R	$33.06 Million
Nephros Inc NASDAQ:NEPH	$33.05 Million
OneMedNet Corp. NASDAQ:ONMD	$33.05 Million
Memscap Regpt PA:MEMS	$33.02 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Grace Therapeutics, Inc.'s equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 61,743,000 to 66,610,000, a change of 4,867,000 (7.9%).
Net loss of 9,568,000 reduced equity.
New share issuances of 14,999,000 increased equity.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	$-9.57 Million	-14.36%
Share Issuances	$15.00 Million	+22.52%
Other Changes	$-564.00K	-0.85%
Total Change	$-	7.88%

Book Value vs Market Value Analysis

This analysis compares Grace Therapeutics, Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 0.42x
The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
The price-to-book ratio has increased from 0.03x to 0.42x over the analyzed period, suggesting growing market confidence.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2010-03-31	$89.25	$2.34	x
2011-03-31	$54.58	$2.34	x
2012-03-31	$103.90	$2.34	x
2013-03-31	$62.66	$2.34	x
2014-03-31	$170.17	$2.34	x
2015-03-31	$120.06	$2.34	x
2016-03-31	$90.45	$2.34	x
2018-03-31	$17.48	$2.34	x
2019-03-31	$9.77	$2.34	x
2020-03-31	$7.37	$2.34	x
2021-03-31	$22.53	$2.34	x
2022-03-31	$17.63	$2.34	x
2023-03-31	$9.14	$2.34	x
2024-03-31	$8.30	$2.34	x
2025-03-31	$5.51	$2.34	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Grace Therapeutics, Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): -14.36%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 0.00%
• Asset Turnover: 0.00x
• Equity Multiplier: 1.08x
Recent ROE (-14.36%) is above the historical average (-81.70%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2010	-37.54%	0.00%	0.00x	2.22x	$-1.91 Million
2011	-52.73%	-10592.29%	0.00x	1.90x	$-3.66 Million
2012	-44.93%	-62421.58%	0.00x	1.09x	$-7.99 Million
2013	-70.88%	-951.66%	0.06x	1.25x	$-7.68 Million
2014	-34.89%	-2318.29%	0.01x	1.37x	$-13.43 Million
2015	-4.98%	-611.68%	0.01x	1.12x	$-3.98 Million
2016	-23.21%	-16777.63%	0.00x	1.05x	$-6.67 Million
2018	-261.49%	0.00%	0.00x	2.79x	$-17.29 Million
2019	-356.41%	0.00%	0.00x	3.34x	$-40.47 Million
2020	-196.34%	0.00%	0.00x	1.76x	$-26.81 Million
2021	-35.35%	-10039.80%	0.00x	1.12x	$-25.24 Million
2022	-9.07%	0.00%	0.00x	1.19x	$-20.65 Million
2023	-62.44%	0.00%	0.00x	1.16x	$-49.22 Million
2024	-20.82%	0.00%	0.00x	1.19x	$-19.03 Million
2025	-14.36%	0.00%	0.00x	1.08x	$-16.23 Million

Industry Comparison

This section compares Grace Therapeutics, Inc.'s net assets metrics with peer companies in the Biotechnology industry.

Industry Context

Industry: Biotechnology
Average net assets among peers: $44,828,400
Average return on equity (ROE) among peers: -124.18%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Grace Therapeutics, Inc. (GRCE)	$62.82 Million	-37.54%	0.06x	$33.06 Million
Aardvark Therapeutics, Inc. Common Stock (AARD)	$-54.64 Million	0.00%	0.00x	$118.88 Million
Abcellera Biologics Inc (ABCL)	$10.25 Million	-21.57%	1.29x	$1.07 Billion
Abeona Therapeutics Inc (ABEO)	$3.60 Million	-91.89%	0.28x	$292.09 Million
Acumen Pharmaceuticals Inc (ABOS)	$266.97 Million	-19.62%	0.16x	$171.87 Million
Abpro Holdings, Inc. (ABP)	$3.07 Million	-479.81%	1.57x	$448.19K
Absci Corp (ABSI)	$67.00 Million	-21.42%	0.32x	$345.85 Million
Arbutus Biopharma Corp (ABUS)	$88.00 Million	-44.09%	0.34x	$840.56 Million
ABVC Biopharma Inc (ABVC)	$80.00K	-31.70%	0.38x	$26.41 Million
Abivax SA American Depositary Shares (ABVX)	$40.58 Million	-434.26%	4.06x	$9.33 Billion
ACADIA Pharmaceuticals Inc (ACAD)	$23.36 Million	-97.44%	0.37x	$3.74 Billion

About Grace Therapeutics, Inc.

NASDAQ:GRCE USA Biotechnology

Market Cap

$33.06 Million

Market Cap Rank

#23390 Global

#4854 in USA

Share Price

$2.34

Change (1 day)

+4.46%

52-Week Range

$2.10 - $5.13

All Time High

$148.80